Tenet Healthcare Corporation New news

The insider sale is characterized as routine profit-taking rather than a sign of concern. The director retained substantial holdings (23,653 shares worth $6.1M), demonstrating continued alignment with the company. The stock has significantly outperformed the market (39% vs S&P 500's 14.8% over one year), and 83% of analysts rate it a buy with a median price target of $284, suggesting positive long-term outlook despite the modest near-term gain potential of 8.4%.

While Tenet received a Buy-equivalent average brokerage recommendation (ABR 1.30) with 77.3% Strong Buy ratings, the article cautions against relying solely on this due to analyst bias. The Zacks Rank #2 (Buy) is more moderately positive, based on modest earnings estimate revisions (+0.3% over the past month). The sentiment is neutral because the article presents this as a case study to illustrate methodological differences rather than making a strong investment case.

THC demonstrates strong fundamentals with 25.4% expected earnings growth, 9.3% USPI revenue growth, raised 2026 EBITDA guidance, consistent earnings beat history (22.7% average surprise), and superior return on assets (5.6% vs 4.4% industry average). The company is successfully expanding its ambulatory platform and managing capital allocation through buybacks.

Strong Q2 results with 50% EPS surprise, 26 consecutive quarters of earnings beats, raised full-year guidance, surging analyst EPS revisions (+17% over 60 days), attractive valuation at 12.6X forward earnings (below sector average), and strong price performance (36% YTD, 250% over 5 years). Zacks Rank #1 (Strong Buy).

Mixed results with earnings beat offset by revenue miss and stock decline of 5.95%. While the company raised full-year earnings guidance and showed strong cash flow growth, management cited headwinds from unfavorable payer mix, winter storms, and cyber attacks. The technical indicators show bearish short-term momentum with the stock trading below key moving averages.

Strong Q4 earnings beat with 8.9% YoY revenue growth, significant EPS improvement (37% increase), robust EBITDA growth, and positive 2026 guidance. Growth across all segments with higher acuity cases and favorable payer mix indicate strong operational execution and market demand.

Tenet is benefiting from stronger hospital activity with 6% YoY revenue growth and 2.3% admission increases, supported by higher acuity care and expanding ambulatory services, demonstrating stronger operational momentum than peers.

Listed as the largest holding in XHS at 2.56% of assets, but no specific performance commentary or analysis is provided in the article.

Added to Zacks Rank #1 Strong Buy list with a 17% increase in consensus earnings estimate over the last 60 days.

Tenet is highlighted as successfully strengthening profitability through operational discipline and growing ambulatory-care platform, with focus on efficiency and higher-acuity care supporting healthier margins and earnings resilience.

Zacks Rank #1 (Strong Buy) with 22.8% expected EPS growth for 2026, consistent earnings beat history (22.7% average surprise), and 4% revenue growth expected.

Fell 12.46% last week amid healthcare sector pressure